You are here

Alnylam

Alnylam Publishes Phase III ATTR-CM Data for Patisiran After FDA Rejection

Alnylam Publishes Phase III ATTR-CM Data for Patisiran After FDA Rejection

BioSpace

clinical trials

ATTR with cardiomyopathy

Flag link:

Interest in RNA Editing Accelerates as Therapies Approach the Clinic

Interest in RNA Editing Accelerates as Therapies Approach the Clinic

BioSpace

Shape Therapeutics

ProQR Therapeutics

Flag link:

Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

Pharma Voice

Yvonne Greenstreet

Flag link:

FDA denies expanded approval for Alnylam RNA drug

FDA denies expanded approval for Alnylam RNA drug

BioPharma Dive

ATTR amyloidosis

Flag link:

With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam

With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam

Fierce Pharma

primary hyperoxaluria type 1

Flag link:

Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts

Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts

Fierce Pharma

clinical trials

Flag link:

Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease

Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease

Fierce Pharma

Flag link:

FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting

FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting

BioSpace

Flag link:

Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win

Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win

BioSpace

clinical trials

Flag link:

Agios and Alnylam sign agreement for siRNA candidate

Agios and Alnylam sign agreement for siRNA candidate

Pharmaceutical Business Review

Agios Pharmaceuticals

polycythemia vera

Flag link:

Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension

Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension

BioSpace

Flag link:

AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress

AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress

BioSpace

Alzheimer's disease

clinical trials

Flag link:

Alnylam and Regeneron report updated positive Phase I results of Alzheimer’s drug

Alnylam and Regeneron report updated positive Phase I results of Alzheimer’s drug

Clinical Trials Arena

clinical trials

Alzheimer's disease

Flag link:

5 FDA decisions to watch in the third quarter

5 FDA decisions to watch in the third quarter

BioPharma Dive

SAGE Therapeutics

Flag link:

Moderna hits back at Alnylam's 'baseless' patent infringement claims

Moderna hits back at Alnylam's 'baseless' patent infringement claims

Fierce Pharma

Moderna Therapeutics

Flag link:

Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle

Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle

BioPharma Dive

clinical trials

Alzheimer's disease

Flag link:

Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam

Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam

Fierce Biotech

Ionis Pharmaceuticals

Flag link:

AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data

AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data

Fierce Biotech

Ionis Pharmaceuticals

clinical trials

Flag link:

JPM Day 1: Highlights

JPM Day 1: Highlights

BioSpace

Sarepta Therapeutics

Arrowhead Pharmaceuticals

Bristol Myers Squibb

Flag link:

Pages